934593-36-9

Upstream product

• 808756-83-4 (1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine 
• 104-15-4 toluene-4-sulfonic acid 
• 253185-03-4 tert-butylbenzene 
• 28547-33-3 1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one 
• 935680-90-3 5-tert-butyl-2,3-dihydro-1H-inden-1-ylamine 
• 4600-86-6 5-(tert-butyl)-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 808756-71-0 N-[(1R)-5-tert-butyl-2,3-dihydro-1H-inden-1-yl]-N'-1H-indazol-4-ylurea 

Relevant academic research and scientific papers

Development of a large scale asymmetric synthesis of vanilloid receptor (TRPV1) antagonist ABT-102

A highly efficient asymmetric synthesis of TRPV1 antagonist ABT-102 was developed and successfully demonstrated on a multi-kilogram scale. This process incorporates a new asymmetric synthesis of (R)-tert-butylaminoindan, which is based on a chiral auxiliary induced diastereoselective reduction of its iminoindan precursor.

Prodrugs of compounds that inhibit TRPV1 receptor

Compounds of formula (I) wherein A, R1, R2, and R3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladd